Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: LeMaitre Vascular develops, manufactures, and markets medical devices and implants for peripheral vascular disease. The company operates in a single segment with eleven product lines, including thoracic and abdominal stent grafts, endovascular accessories, and the recently acquired LeverEdge Contrast Injector. The company completed its Initial Public Offering (IPO) in October 2006.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2007 |
Six Months Ended June 30, 2007 |
Six Months Ended June 30, 2006 |
|---|---|---|---|
| Net Sales | $10,315 | $20,198 | $17,331 |
| Gross Profit | $7,613 | $14,983 | $12,405 |
| Gross Margin | 73.8% | 74.2% | 71.6% |
| Operating Loss | $(447) | $(1,425) | $(588) |
| Net Income (Loss) | $227 | $(402) | $(719) |
| Cash and Cash Equivalents | $12,474 | $12,474 | $666 |
| Marketable Securities | $15,459 | $15,459 | N/A |
| Total Current Assets | $42,692 | $42,692 | N/A |
| Total Liabilities | $5,732 | $5,732 | N/A |
Liquidity: As of June 30, 2007, the company held $27.9 million in combined cash, cash equivalents, and marketable securities. The company maintains a $5.5 million revolving line of credit with no outstanding balance as of the reporting date.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 18% for the quarter and 17% for the six-month period compared to the prior year. Growth was driven by a 45-46% increase in the Endovascular & Dialysis Access category and a 32-34% increase in sales outside the U.S. and Canada.
- Profitability: The company reported a net income of $227,000 for the quarter ended June 30, 2007, compared to a net loss of $1.1 million in the same period in 2006. However, the six-month period ended June 30, 2007, resulted in a net loss of $402,000, an improvement from the $719,000 loss in the prior year.
- Operating Expenses: Sales and marketing expenses increased 34% year-over-year for the six-month period due to the expansion of the sales force from 37 to 48 representatives. General and administrative expenses rose 30%, attributed to costs associated with being a public company.
- Impairment Charges: The prior year period included a $406,000 impairment charge related to the Expedial Vascular Access Graft product line, which was not present in the current period.
- Acquisition: In April 2007, the company acquired Cardiovascular Innovations, LLC for $432,000 to enter the hand-powered contrast injector market.
Guidance, Outlook, and Risks
Outlook: Management expects to continue operating with a net operating loss for the remainder of 2007 due to investments in growth strategies and public company expenses. The company anticipates that increased operating expenses will offset revenue growth, leading to a net loss for the full year 2007.
Key Risks and Contingencies:
- Tax Audits: The company is subject to audits by the IRS (2004-2005 returns settled in April 2007) and German tax authorities (2004-2006 filings). A liability of approximately $0.6 million exists for unrecognized tax benefits.
- Regulatory Approvals: Corruption scandals within the Chinese State Food and Drug Administration (SFDA) may delay or prevent approval for the EndoFit Thoracic Stent Graft in China.
- Product Recalls: The company initiated a voluntary recall in 2007 regarding packaging flaws in the acquired LeverEdge Contrast Injector inventory.
- Foreign Currency: Approximately 41% of sales are denominated in foreign currencies (primarily Euro), exposing the company to exchange rate fluctuations.
- Capital Needs: While current cash reserves are deemed sufficient for the foreseeable future, the company may require additional financing for future acquisitions.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $1.8 million net cash used in operating activities for the six-month period against current cash reserves of $27.9 million.
- Inventory Levels: Review the $1.1 million increase in inventory ($7.3 million total) to ensure it aligns with sales growth and does not indicate obsolescence risks.
- Debt Covenants: Confirm the status of the $5.5 million revolving credit facility, noting the filing states the company was "not in compliance with certain of these covenants" as of June 30, 2007, despite having no outstanding balance.
- Acquisition Integration: Assess the revenue contribution and integration costs of the Cardiovascular Innovations, LLC acquisition.
- Tax Provision: Monitor the resolution of the German tax audit and the realization of the $0.5 million U.S. federal income tax carry-back claim from the Japanese subsidiary reorganization.